Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 11/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1806005 | 1.00 | ERN1 (0.55) | ERN1RXRAFBP1PRMT1VCP | |
| SCHEMBL1805981 | 0.82 | RXRA (0.54) | ERN1RXRAFBP1PRMT1EGFR | |
| SCHEMBL17103950 | 0.82 | RXRA (0.54) | RXRAFBP1PRMT1VCPTLR4 | |
| SCHEMBL1805984 | 0.82 | RXRA (0.54) | ERN1RXRAFBP1PRMT1EGFR | |
| SCHEMBL17103952 | 0.82 | RXRA (0.54) | RXRAFBP1PRMT1VCPTLR4 | |
| SCHEMBL470811 | 0.82 | NFE2L2 (0.58) | RXRAFBP1PRMT1VCPTLR4 | |
| SCHEMBL30914655 | 0.82 | NFE2L2 (0.58) | RXRAFBP1PRMT1VCPTLR4 | |
| SCHEMBL4723192 | 0.82 | NFE2L2 (0.58) | RXRAFBP1PRMT1VCPTLR4 | |
| SCHEMBL17104088 | 0.79 | RXRA (0.51) | RXRAFBP1PRMT1VCPTLR4 | |
| SCHEMBL1805948 | 0.79 | RXRA (0.51) | ERN1RXRAFBP1PRMT1VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | ERN1 4806/4885RXRA 1561/4885FBP1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.